SEC Form SC 13G/A filed by PTC Therapeutics Inc. (Amendment)
$PTCT
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/17/2025 | $80.00 | Buy | Truist |
| 5/9/2025 | $68.00 | Neutral → Buy | BofA Securities |
| 5/7/2025 | $40.00 | Sell → Neutral | Citigroup |
| 3/11/2025 | $41.00 → $55.00 | Underperform → Neutral | BofA Securities |
| 3/7/2025 | $55.00 | Sector Perform | Scotiabank |
| 12/13/2024 | $45.00 → $67.00 | Equal-Weight → Overweight | Morgan Stanley |
| 12/3/2024 | $39.00 → $63.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 10/10/2024 | Mkt Perform | Raymond James |
4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f
Truist initiated coverage of PTC Therapeutics with a rating of Buy and set a new price target of $80.00
BofA Securities upgraded PTC Therapeutics from Neutral to Buy and set a new price target of $68.00
Citigroup upgraded PTC Therapeutics from Sell to Neutral and set a new price target of $40.00
8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
10-Q - PTC THERAPEUTICS, INC. (0001070081) (Filer)
8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)
WARREN, N.J., Aug. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) related to the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia. "We are of course disappointed by the FDA's decision to not approve vatiquinone," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "We believe the data collected to date demonstrate that vatiquinone could provide a safe and effective therapy for both children and adults living with Friedreich's ataxia. We plan to meet with the FDA to discuss potentia
– European and FDA approval of Sephience™ (sepiapterin) with broad labeling for PKU – – Global launch underway in Europe and U.S. – – Total Q2 Revenue of $179M – WARREN, N.J., Aug. 7, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2025. "We had another strong quarter highlighted by the first approvals of Sephience for the treatment of children and adults with PKU," said Matthew B. Klein, M.D., Chief Executive Officer. "We have initiated the global launch and expect Sephience to be the foundational product for PTC's future growth and path to profitability." Key Corporate Updates: Sec
- Broad labeling inclusive of all disease subtypes for individuals 1 month of age and older - - PTC will host a conference call on Monday, July 28th at 5:00 pm ET - WARREN, N.J., July 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the U.S. Food and Drug Administration (FDA) has approved SEPHIENCE™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU). The approval includes broad labeling for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive PKU. "We are excited to have reached this important milestone for those affected by PKU," said Matthew
4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)
SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)
SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)
SC 13G/A - PTC THERAPEUTICS, INC. (0001070081) (Subject)
BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. "We are excited to welcome David to our Board," said Dick Simon, Chief Executive Officer of Sensorium. "He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages. David's depth of experience will be a key asset as we advance our lead program, SENS-01, towards the clinic and expand our drug pipeline into addition
SOUTH PLAINFIELD, N.J., July 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the appointment of Pierre Gravier to the role of Chief Financial Officer (CFO). Mr. Gravier brings more than 17 years of experience as an investment banker, venture capitalist and scientist to PTC. Most recently, Pierre was a managing director in the healthcare group of Perella Weinberg Partners, a leading independent global advisory firm. At Perella Weinberg, he focused on advising companies in the biopharmaceutical and pharmaceutical sectors on finance strategy and corporate development. "We are incredibly excited to have Pierre as part of PTC's leadership team," said Matthew B. Klein
– European and FDA approval of Sephience™ (sepiapterin) with broad labeling for PKU – – Global launch underway in Europe and U.S. – – Total Q2 Revenue of $179M – WARREN, N.J., Aug. 7, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2025. "We had another strong quarter highlighted by the first approvals of Sephience for the treatment of children and adults with PKU," said Matthew B. Klein, M.D., Chief Executive Officer. "We have initiated the global launch and expect Sephience to be the foundational product for PTC's future growth and path to profitability." Key Corporate Updates: Sec
- Broad labeling inclusive of all disease subtypes for individuals 1 month of age and older - - PTC will host a conference call on Monday, July 28th at 5:00 pm ET - WARREN, N.J., July 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the U.S. Food and Drug Administration (FDA) has approved SEPHIENCE™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU). The approval includes broad labeling for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive PKU. "We are excited to have reached this important milestone for those affected by PKU," said Matthew
WARREN, N.J., July 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its second quarter 2025 financial results and provide an update on the company's business and outlook on Thursday, August 7, at 4:30 p.m. ET. To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in for the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Invest